Medical Practice Valuation Guide [2026]
Whether you're considering selling your practice, negotiating a private equity offer, buying into a partnership, or simply planning your estate, understanding what your medical practice is worth is foundational. Practice valuation is not just a number on a page — it determines the trajectory of your career, your retirement, and your legacy. If a sale is on the horizon, our guide to selling a medical practice walks through the full transaction process from preparation to closing.
The problem: most physicians underestimate their practice's value or, worse, rely on a buyer's valuation as the basis for a transaction. PE firms and hospital systems employ teams of analysts who know exactly what your practice is worth to them. If you don't have an independent, defensible valuation of your own, you are negotiating blind against a counterparty who has every incentive to minimize what they pay.
A comprehensive framework for understanding medical practice valuation — including 2026 specialty-specific multiples, valuation methodology comparisons, PE deal benchmarks, an interactive valuation estimator, and a readiness scorecard across 10 key value drivers.
GetPracticeHelp.com is an independent comparison platform. Some of the services referenced in this guide are affiliate partners — we may earn a commission if you sign up through our links, at no extra cost to you. Our evaluations are based on publicly available information and verified product details, and affiliate relationships do not influence our rankings or recommendations.
Part 1: Why Valuation Matters — It's Not Just for Selling
Many physicians assume that practice valuation is only relevant when you're ready to sell. In reality, a current, defensible valuation is required — or strongly advisable — in a wide range of situations that affect every stage of your career.
Stark Law FMV Compliance
Under the Stark Law physician self-referral prohibition (42 U.S.C. § 1395nn) and its implementing regulations at 42 CFR Part 411 Subpart J, virtually every compensation arrangement between a physician and a DHS entity must be consistent with fair market value. Practice acquisitions, physician buy-ins, equipment leases, and medical directorships all require FMV documentation. Failure to establish FMV can result in False Claims Act liability, treble damages, and exclusion from federal healthcare programs.
Private Equity & MSO Offers
PE firms completed 79 physician practice deals in Q1 2025 alone, with particular focus on cardiology, dermatology, orthopedics, and behavioral health. When a PE buyer or Management Services Organization (MSO) presents an offer, you need an independent baseline valuation to evaluate whether their number represents fair value — or a discount designed to maximize their returns at your expense.
Partner Buy-Ins & Buy-Outs
When a new physician buys into your practice or an existing partner departs, the transaction price must reflect current fair market value. Without a formal valuation, buy-in negotiations become adversarial guessing games. Worse, if the price is above or below FMV, the arrangement may violate the Anti-Kickback Statute (42 U.S.C. § 1320a-7b) safe harbor requirements at 42 CFR § 1001.952.
Estate & Succession Planning
Your practice is likely one of your largest assets. For estate tax purposes, the IRS requires fair market value determinations under Revenue Ruling 59-60. Without a contemporaneous valuation, your estate may face challenges, penalties, or an unfavorable IRS audit. A current valuation also supports gift planning, charitable contributions, and equitable wealth transfer to heirs.
Partnership Disputes & Divorce
Business valuations are frequently contested in partnership dissolution, shareholder disputes, and marital divorce proceedings. Courts rely on qualified appraisals to adjudicate the value of professional practice goodwill — both personal goodwill (attributable to the individual physician) and enterprise goodwill (transferable to a buyer). Having a current, credentialed valuation prevents costly litigation battles over methodology and assumptions.
Strategic Decision-Making
A valuation provides a financial baseline for every major decision: Should you invest in a new EHR? Expand to a second location? Add ancillary services? Understanding your current practice value — and what drives that value — transforms these from gut decisions into data-driven investments with measurable ROI against your enterprise value.
Part 2: Valuation Methods Explained
Professional appraisers (CVA, ABV, ASA credentials) use three primary approaches to value medical practices, as codified by the AICPA Statement on Standards for Valuation Services (SSVS VS Section 100), NACVA Professional Standards, and the Uniform Standards of Professional Appraisal Practice (USPAP). Most credible valuations apply multiple approaches and reconcile the results.
Asset Approach (Cost Approach)
Values the practice based on the adjusted net book value of its tangible and intangible assets minus liabilities. Starts with the balance sheet and adjusts assets to current fair market value — including equipment, furniture, real estate, accounts receivable, and any identified intangible assets like assembled workforce or a favorable lease.
Income Approach (DCF / Capitalization of Earnings)
Values the practice based on the present value of its expected future cash flows. The most common methods are Discounted Cash Flow (DCF), which projects future earnings and discounts them to present value using a risk-adjusted rate (typically 10–25% for physician practices), and Capitalization of Earnings, which divides normalized earnings by a capitalization rate.
Market Approach (Comparable Transactions)
Values the practice by reference to the selling prices of comparable practices in recent arm's-length transactions. Uses revenue multiples (e.g., 0.5–1.0× for smaller practices) or EBITDA multiples (e.g., 5–12×) derived from transaction databases maintained by VMG Health, HealthCare Appraisers, Provident Healthcare Partners, BVR, and others.
Rule-of-Thumb Multiples
Informal valuation benchmarks commonly cited in physician practice transactions — e.g., "primary care practices sell for 0.5–0.7× revenue" or "dermatology sells for 6–8× EBITDA." These are not formal valuation methods and should never be used as the sole basis for a transaction. They are starting points for initial screening, not substitutes for a qualified appraisal.
Part 3: 2026 Specialty-Specific Valuation Multiples
The following table presents current 2025–2026 revenue and EBITDA multiples by medical specialty. Multiples vary significantly based on practice size (small add-on vs. large platform), payer mix, ancillary services, and geographic market. These ranges are synthesized from transaction data compiled by FOCUS Investment Banking, VMG Health, Sofer Advisors, Scope Research, HealthCare Appraisers, and Provident Healthcare Partners.
| Specialty | Revenue Multiple | EBITDA Multiple Add-On / Small |
EBITDA Multiple Platform / Large |
PE Interest 2025–2026 |
|---|---|---|---|---|
| Primary Care (Family / Internal Medicine) | 0.4–0.7× | 3–6× | 8–12× | Moderate |
| Cardiology | 0.7–1.2× | 8–12× | 12–15× | Very High |
| Orthopedics & Sports Medicine | 0.6–1.0× | 6–9× | 9–13× | High |
| Dermatology | 0.6–1.0× | 4–8× | 10–15× | High |
| Ophthalmology (incl. Retina) | 0.7–1.3× | 7–11× | 12–20× | Very High |
| Gastroenterology | 0.7–1.2× | 7–9× | 10–14× | Very High |
| Oncology / Urology | 0.8–1.3× | 8–12× | 14–19× | High |
| OB/GYN & Women's Health | 0.5–0.9× | 5–8× | 10–14× | Moderate |
| Pain Management | 0.5–0.8× | 5–8× | 8–11× | Moderate |
| Behavioral Health (Mental Health) | 0.6–1.0× | 4–8× | 10–14× | High |
| Dental (DSO) | 0.6–1.0× | 5–8× | 9–12× | High |
| Urgent Care | 0.7–1.3× | 5–8× | 8–13× | Moderate |
| Plastic Surgery & Aesthetics | 0.5–1.0× | 4–8× | 8–12× | Moderate |
Sources: FOCUS Investment Banking (2026), Sofer Advisors (2025–2026), Covenant Health Advisors (2025), Scope Research (2025), VMG Health M&A Report (2025), HealthCare Appraisers. Multiples reflect consensus data from 2024–2026 transactions. Platform multiples assume practices with $5M+ EBITDA, centralized infrastructure, and multi-site operations.
Key Factors That Adjust Multiples Up or Down
| Factor | Effect on Multiple | Rationale |
|---|---|---|
| Ancillary revenue (ASC, imaging, pathology) | +1–3× EBITDA | High-margin revenue streams reduce buyer risk and enhance profitability |
| Strong commercial payer mix (>60%) | +1–2× EBITDA | Commercial payers reimburse ~89% more than Medicare on average |
| Revenue growth trajectory (>10% CAGR) | +1–3× EBITDA | Growth runway signals scalability and expansion potential |
| Geographic density / market dominance | +1–2× EBITDA | Referral control and negotiating leverage with payers |
| Associate-driven model (low key-person risk) | +1–2× EBITDA | Practice sustainability beyond the founding physician |
| High owner-dependency (key-person risk) | −1–3× EBITDA | Revenue may decline significantly if founding physician departs |
| Heavy Medicare/Medicaid mix (>60%) | −1–2× EBITDA | Lower reimbursement rates and legislative/regulatory risk |
| Outdated EHR/technology stack | −0.5–1× EBITDA | Buyer must invest in technology modernization post-close |
| Compliance deficiencies | −1–3× EBITDA | Regulatory risk, potential False Claims Act exposure, remediation cost |
Part 4: PE & MSO Acquisition Landscape
Private equity investment in physician practices accelerated through 2024–2025, with deal activity expected to remain elevated into 2026 as interest rate stabilization improves financing conditions. According to the Private Equity Stakeholder Project, PESP tracked over 1,029 PE-backed healthcare transactions in 2025 — including 151 platform acquisitions, 664 add-on deals, and 214 growth investments.
Across publicly traded healthcare services companies, the median EV/EBITDA multiple declined to approximately 11.5× in 2025, down from 14.5× in 2024, reflecting higher borrowing costs and increased buyer selectivity compared to the record valuations seen in 2021–2022. However, competition for well-run specialty groups continues to drive double-digit pricing across key segments — particularly cardiology, ophthalmology, gastroenterology, and behavioral health.
Typical PE Deal Structures for Physician Practices
| Deal Component | Typical Terms | What to Watch For |
|---|---|---|
| Transaction Structure | "Friendly PC" / MSO model — PE-backed MSO acquires non-clinical assets and enters into a management services agreement (MSA) with the physician-owned professional corporation (PC). The MSO employs non-clinical staff and provides administrative services; the PC retains clinical autonomy and employs physicians. | Directed equity transfer agreements that give the MSO effective control over the PC's physician-owner replacement. Ensure compliance with your state's corporate practice of medicine (CPOM) doctrine. In CPOM states, laypersons cannot own or control a medical practice directly. |
| Purchase Price | Based on EBITDA multiple (see Part 3). Typically 60–80% cash at close, with 20–40% in seller rollover equity (ownership stake in the MSO/platform). Rollover equity aligns physician incentives with PE's growth objectives and offers a potential "second bite of the apple" upon PE exit. | Verify that the EBITDA figure used includes proper add-backs (one-time expenses, above-market owner comp). Ensure the purchase price is at or below FMV to avoid Stark Law and AKS exposure. Overpaying above FMV can be construed as remuneration for referrals. |
| Earnout Provisions | Additional payments (typically 10–25% of total consideration) contingent on the practice meeting revenue, EBITDA, or patient retention targets over 1–3 years post-close. Metrics should be clearly defined and objectively measurable. | Ensure earn-out metrics use clear accounting definitions (cash vs. accrual). Avoid metrics that incentivize referral volume — the Anti-Kickback Statute safe harbors at 42 CFR § 1001.952 require that compensation not vary with referral volume or value. Performance reviews should be at specified intervals with defined dispute resolution. |
| Post-Close Employment | Most PE buyers require a 3–5 year minimum employment commitment from selling physicians. Compensation typically 30–35% of collections or net production, often less than pre-sale take-home pay. Clinical expectations include defined production days and patient volume minimums. | Negotiate flexibility on scheduling, phased retirement options, and clear definitions of "production" and "collections." Note: requesting higher post-close salary often results in a lower EBITDA multiple (and therefore lower closing cash). More salary now = less purchase price at close. |
| Non-Compete / Non-Solicit | Typically 1–2 years post-termination. Geographic radius of 5–25 miles depending on metro vs. rural. Non-solicitation of patients and staff for 2+ years. Enforceability varies by state — some states (California, Oklahoma, North Dakota, Minnesota) severely restrict non-competes. | Negotiate narrower geographic radius, exceptions for teaching or hospital privileges, and carve-outs for specific practice types (e.g., concierge medicine, locum tenens). Ensure the non-compete terminates if the buyer materially breaches the employment agreement. |
| Management Fee / MSA | MSO charges the physician practice a management fee — either a flat fee, expenses plus markup, or a percentage of gross/net revenue (typically 10–20% of net revenue). The fee covers administrative staff, billing, office space, equipment, and management services. | In states with fee-splitting prohibitions, percentage-of-revenue fee structures between physicians and MSOs may be restricted. The MSA fee must represent FMV for the services actually provided — not a disguised profit-sharing mechanism. Require an independent FMV opinion on the management fee. |
Part 5: Preparing for Maximum Value — 12–24 Month Timeline
The single biggest mistake physicians make when selling their practice is starting too late. The best time to prepare for a sale — whether to a PE firm, a health system, or another physician — is 12–24 months before going to market. This preparation window allows you to optimize EBITDA, reduce key-person risk, clean up financials, and address any issues that would cause a buyer to discount your valuation. Understanding your practice overhead costs is essential to normalizing financials and presenting clean numbers to buyers.
Financial & Operational Baseline
- Commission an independent practice valuation to establish your baseline value and identify specific value drivers and detractors
- Engage a healthcare CPA to normalize 3–5 years of financial statements — remove personal expenses, one-time costs, above-market owner compensation, and non-operating items
- Document all revenue sources, payer contracts, and fee schedules in a centralized file
- Conduct an internal compliance audit — review coding accuracy, billing practices, HIPAA policies, and OSHA compliance
- Assess your EHR and technology stack — outdated systems cost 0.5–1× EBITDA in buyer discounts
EBITDA Enhancement & Risk Reduction
- Renegotiate payer contracts (target 5–15% rate increases on commercial contracts — even a 5% rate increase flows directly to EBITDA)
- Reduce overhead: audit supply costs, renegotiate lease terms, eliminate redundant subscriptions and services
- Hire or develop associate providers to reduce key-person dependency — buyers pay 1–2 additional EBITDA turns for practices where the founding physician is not the primary revenue generator
- If feasible, add ancillary services (imaging, lab, procedures) that increase revenue diversification and margin — ancillaries can add 1–3 EBITDA turns
- Document all operating procedures, clinical protocols, and administrative workflows — a buyer wants a turnkey operation, not tribal knowledge
Pre-Market Positioning
- Refresh your valuation with updated financials reflecting 12+ months of optimization
- Prepare a confidential information memorandum (CIM) or practice summary for prospective buyers
- Engage a healthcare M&A advisor or investment banker (typical fee: 3–8% of transaction value as a success fee, sometimes with a retainer)
- Identify 5–10 potential buyers (PE platforms, strategic acquirers, health systems, or physician groups) and prioritize based on cultural fit, geographic interest, and deal history
- Resolve any pending litigation, compliance issues, or credentialing gaps before a buyer's due diligence team discovers them
Negotiation, Due Diligence & Close
- Receive Letters of Intent (LOIs) from interested buyers — compare total consideration, deal structure, employment terms, and timeline
- Select your preferred buyer and enter exclusivity (typically 60–90 days for due diligence)
- Cooperate with buyer's due diligence: financial audits, legal review, regulatory compliance, payer contract assignments, provider credentialing verification
- Negotiate definitive agreements: purchase agreement, employment contracts, non-compete, MSA (if MSO structure), and any ancillary agreements
- Close the transaction — ensure all Stark Law, AKS, and state regulatory requirements are satisfied, including required state attorney general notifications (varies by state)
Practice Valuation Estimator
Estimate Your Practice Value
Enter your practice's key financial metrics to get a preliminary valuation range using 2026 specialty-specific multiples.
Estimated Valuation Range
Factors That Could Increase Value
Factors That Could Decrease Value
Valuation Readiness Scorecard
Rate your practice across 10 key value drivers that buyers evaluate during due diligence. Each driver is scored 1–5, with 5 being strongest. Your total score (out of 50) indicates how ready your practice is to command a premium valuation.
Rate Your 10 Value Drivers
Score each driver 1 (weakest) to 5 (strongest) based on your honest assessment.
-
1Revenue Growth TrendYear-over-year revenue growth over the past 3 years. Positive trajectory signals a growing, healthy practice. Declining revenue raises red flags for buyers.
-
2Payer Mix QualityProportion of commercial vs. government payers. Higher commercial mix = higher margins and stronger multiples. Commercial payers reimburse ~89% more than Medicare on average.
-
3Provider Diversification (Key-Person Risk)Does the practice depend on one provider for the majority of revenue? Associate-driven models command 1–2 additional EBITDA turns. High key-person risk is the #1 valuation detractor.
-
4Facility & Equipment ConditionModern, well-maintained facilities and equipment reduce post-close capital requirements for buyers. Outdated equipment and deferred maintenance signal hidden costs.
-
5Staff Stability & DepthLow turnover, tenured staff, and depth in key roles (billing manager, office manager, lead clinical staff) signal operational stability. High turnover is a red flag during due diligence.
-
6EHR & Technology StackModern, interoperable EHR system (eClinicalWorks, athenahealth, Epic, etc.), digital patient intake, telehealth capabilities, and automated workflows. Outdated tech costs 0.5–1× EBITDA in buyer discounts.
-
7Compliance Program MaturityDocumented compliance plan, regular coding audits, HIPAA policies, OIG exclusion screening, annual risk assessments. Compliance deficiencies can cost 1–3× EBITDA in valuation discounts and create deal-killing due diligence findings.
-
8Patient Base Size & DemographicsActive patient panel size, patient demographics (age, insurance status), retention rates, and new patient acquisition trends. A growing, commercially insured patient base in a favorable demographic market commands premiums.
-
9Market Position & CompetitionAre you the dominant provider in your market, or one of many? Geographic density, brand recognition, referral network strength, and competitive landscape all affect strategic value. Buyers pay +1–2× EBITDA for market leaders.
-
10Financial Documentation QualityClean, accurate, CPA-reviewed financial statements for 3–5 years. Normalized EBITDA calculations with documented add-backs. Clear revenue breakdown by provider, payer, and service line. Poor financials delay deals and reduce buyer confidence.
—
Frequently Asked Questions
Fair market value (FMV) represents the price a willing buyer and willing seller would agree upon, with both parties having reasonable knowledge of the relevant facts and neither under compulsion to act. Strategic value exceeds FMV by incorporating synergies a specific buyer expects to achieve — such as geographic expansion, payer contract leverage, ancillary revenue integration, or multiple arbitrage (buying small practices at low multiples and rolling them into a platform valued at higher multiples).
Under Stark Law (42 CFR § 411.351), physician practice transactions involving designated health services must be at FMV. PE buyers often pay strategic premiums of 1–3 additional EBITDA multiple turns above FMV for practices that unlock platform-level synergies — but any ongoing compensation arrangement between the buyer and physician post-close must still be at FMV to satisfy regulatory requirements.
A formal practice valuation from a credentialed appraiser (CVA, ABV, or ASA) typically costs $5,000–$30,000 depending on practice complexity, number of providers, and scope of the engagement. Solo practices with straightforward financials may fall in the $5,000–$10,000 range. Multi-provider specialty groups with ancillary services, real estate, and complex payer mixes can cost $15,000–$30,000 or more.
A "calculation of value" (a less detailed engagement under AICPA SSVS standards) may cost $3,000–$8,000. This is appropriate for internal planning or preliminary deal analysis but may not satisfy Stark Law, estate tax, or litigation requirements. The investment is modest compared to the financial consequences of mispricing a transaction worth hundreds of thousands to millions of dollars.
Yes. Under the Stark Law physician self-referral prohibition (42 U.S.C. § 1395nn) and its implementing regulations at 42 CFR Part 411 Subpart J, virtually every compensation arrangement between a physician and an entity that furnishes designated health services must be consistent with fair market value and not take into account the volume or value of referrals. This applies to practice acquisitions, physician employment agreements, partner buy-ins, equipment and office space leases, and medical directorships.
While the law does not explicitly mandate a formal appraisal, the OIG and CMS strongly recommend a contemporaneous, well-documented FMV determination prepared by an independent, qualified appraiser. In the event of an audit, self-disclosure, or False Claims Act investigation, having a credentialed appraisal is your primary evidence that the arrangement satisfies the FMV requirement.
In 2026, medical practices typically sell for 5–12× EBITDA, with significant variation by specialty and practice size. Primary care practices average 3–6× for smaller groups and 8–12× for scaled value-based platforms. High-demand specialties command premium multiples: cardiology (8–15×), gastroenterology (7–14×), ophthalmology (7–20×), dermatology (4–15×), and orthopedics (6–13×).
Practice size is the single largest driver — practices with $5M+ EBITDA consistently achieve 2–4 additional multiple turns compared to smaller add-on acquisitions. Median healthcare services EV/EBITDA multiples moderated to approximately 11.5× in 2025 (from 14.5× in 2024) across publicly traded companies, but competition for well-run specialty groups continues to support double-digit pricing.
A comprehensive practice valuation typically takes 4–8 weeks from engagement to final report delivery. The timeline includes 1–2 weeks for data collection (financial statements, tax returns, payer contracts, provider agreements), 2–4 weeks for analysis and report drafting, and 1–2 weeks for review and finalization. Complex multi-provider practices with ancillary operations may take 8–12 weeks.
A calculation engagement — less detailed than a full appraisal — can often be completed in 2–4 weeks. If you're anticipating a transaction or event that requires a valuation, engage the appraiser early. Last-minute valuations are more expensive and may require the appraiser to use shortcuts that weaken the report's defensibility.
In professional valuation standards (AICPA SSVS, NACVA, ASA), the terms refer to different levels of service. A "valuation engagement" (or "conclusion of value") provides the highest level of assurance — the appraiser performs all procedures deemed necessary and issues a conclusion of value without restriction as to the approaches or methods considered. A "calculation engagement" (or "calculation of value") applies agreed-upon approaches and assumptions with a more limited scope, resulting in a calculated value rather than a conclusion.
For Stark Law compliance, estate/gift tax, and litigation, a full valuation engagement is typically required. For internal planning or preliminary deal analysis, a calculation engagement may suffice. Always discuss the appropriate level of service with your appraiser before engagement — upgrading mid-engagement is expensive and disruptive.
Absolutely. Obtaining an independent valuation before engaging with PE buyers or MSOs is one of the most important steps a practice owner can take. Without a baseline valuation, you have no leverage in negotiations and no objective basis for evaluating whether an offer represents fair value.
PE firms perform their own detailed underwriting — they arrive at the table knowing exactly what your practice is worth to them (and often structuring their offer to minimize what they pay while maximizing their returns). An independent valuation levels the playing field and identifies areas where you can improve value before going to market — potentially adding 1–3 EBITDA multiple turns to your ultimate sale price through EBITDA optimization, key-person risk reduction, and financial documentation improvements.
The federal Anti-Kickback Statute (42 U.S.C. § 1320a-7b) prohibits offering, paying, soliciting, or receiving anything of value to induce or reward referrals for services covered by federal healthcare programs. For practice acquisitions, the investment interest safe harbor (42 CFR § 1001.952(a)) and the personal services safe harbor (42 CFR § 1001.952(d)) are most relevant.
To qualify, compensation must be consistent with fair market value, must be commercially reasonable, and must not vary with the volume or value of referrals. Overpaying for a practice — or structuring earn-outs tied to referral volume — can trigger AKS exposure even if the parties did not intend a kickback arrangement. The 2020 OIG final rule added the value-based arrangement safe harbors, but these are narrow and require specific care coordination and cost-saving structures.
Whether buying, selling, or evaluating your practice, the right financial tools make all the difference.
Browse Recommended Partners →